Ian Flinn, MD, PhD, Tennessee Oncology, Nashville, TN, discusses a Phase Ib trial (NCT03400176) of ianalumab plus ibrutinib in patients with chronic lymphocytic leukemia (CLL) receiving ibrutinib therapy. Ianalumab (VAY736) is an anti-BAFF-R monoclonal antibody that causes antibody-dependent cellular cytotoxicity of B-cells. It is hoped that its addition to ibrutinib will deepen responses through synergistic activity, allowing discontinuation of ibrutinib and prevention of cumulative toxicity. Patients were enrolled who had developed ibrutinib resistance, or not achieved a complete remission with over 1 year of treatment. The trial has shown manageable safety and promising preliminary efficacy results, with 20% achieving measurable residual disease (MRD) negativity and discontinuing therapy. Investigations into the combination are ongoing. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.